Bolder BioTechnology, Inc. Protein Image
About Bolder BioTechnology

Date:
Company Profile

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are eliminated rapidly by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. Our products are designed to last longer in the body, which allows them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Our diversified product pipeline includes treatments for hematological and endocrine disorders, cancer and infectious diseases. We intend to commercialize these products independently and through strategic alliances with corporate partners.

 

News

08-02-2017
Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome
     Details

11-11-2015
U.S. Department of Defense to Fund Research at Indiana University and Epistem UK Investigating Treatments for Radiation Sickness
     Details

06-12-2015
Bolder BioTechnology Receives Continued NIH Support For Preclinical Development of a Long-Acting Blood Cell Growth Factor to Treat Hematopoietic Complications of Acute Radiation Exposure
     Details

06-12-2015
Bolder BioTechnology Receives Third Year of NIH Grant to Study Use of Blood Cell Growth Factors to Treat Acute Radiation Syndrome
     Details

05-29-2014
Bolder BioTechnology Receives Continued NIH Support to Study Effects of Long-Acting Growth Factors for Treating Acute Radiation Syndrome
     Details

08-28-2012
Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
     Details

11-03-2010
Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
     Details

8-18-2010
Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome...
     Details

View all news



About Us - Technology - Products - People - News - Careers - Contact Us

Copyright © 2009 - 2016. Bolder BioTechnology, Inc. All Rights Reserved.
Disclaimer